GENE MANIPULATION
- PMID: 40367262
- Bookshelf ID: NBK614241
GENE MANIPULATION
© Thalassaemia International Federation.
Conflict of interest statement
FL reports participating in speaker’s bureau with Amgen, Bristol Myers Squibb, Miltenyi Biotec, Neovii, Novartis, SOBI and Vertex Pharmaceuticals; and consultancy for Sanofi, Vertex Pharmaceuticals and Amgen; and honoraria, advisory board participation for Amgen. MA reports scientific advisory board and steering committee participation for Vertex Pharmaceuticals. All competing interests are outside the present work.
Sections
References
-
- Magrin E, Miccio A, Cavazzana M Lentiviral and genome-editing strategies for the treatment of betahemoglobinopathies. Blood. 2019;134(15):1203–1213. - PubMed
-
- Algeri M, Lodi M, Locatelli F Hematopoietic Stem Cell Transplantation in Thalassemia. Hematol Oncol Clin North Am. 2023;37(2):413–432. - PubMed
-
- Cline MJ Perspectives for gene therapy: inserting new genetic information into mammalian cells by physical techniques and viral vectors. Pharmacol Ther. 1985;29(1):69–92. - PubMed
-
- Ferrari G, Thrasher AJ, Aiuti A Gene therapy using haematopoietic stem and progenitor cells. Nat Rev Genet. 2021;22(4):216–234. - PubMed
Publication types
LinkOut - more resources
Full Text Sources